Evidence map›Paper›PMID 40938574›Full record

Observational studyInternational journal of hematology2026

Long-term immunity to measles and rubella after vaccination in adult allogeneic hematopoietic stem cell transplant recipients.

Satoshi Dohtan, Yasuyuki Nagata, Mitsuru Yamashita, Ryo Ikeda, Katsumi Koyauchi, Fumisato Takagi, Satoshi Uchiyama, Shinichiro Oka, Miwa Adachi, Kozue Mitsui and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Satoshi DohtanDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan. cbf16237@gmail.com.ORCID http://orcid.org/0009-0006-4768-5010
Yasuyuki NagataDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Mitsuru YamashitaDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Ryo IkedaDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Katsumi KoyauchiDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Fumisato TakagiDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Satoshi UchiyamaDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Shinichiro OkaDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Miwa AdachiDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Kozue MitsuiTransplantation Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tomonari TakemuraDivision of Hematology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuoh-ku, Hamamatsu, 431-3192, Japan.
Takaaki OnoTransfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outbreaks of measles and rubella occasionally occur, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients face an increased risk of mortality from measles. This retrospective observational study assessed immunological responses to MR vaccination and long-term changes in antibody titers in adult allo-HSCT recipients. The measles and rubella cohorts included 36 and 33 patients, respectively, who received MR vaccination between March 2010 and December 2023. MR vaccination significantly increased IgG titers against measles from 5.48 (± 3.61) at T0 (pre-vaccination) to 14.15 (± 10.31) at T1 (1 year post-vaccination) and against rubella from 3.90 (± 2.82) at T0 to 58.93 (± 44.46) at T1 (both p < 0.001). Multivariate analyses in the measles cohort showed that lower IgG antibody titers at T0 were significantly associated with high responder status (OR 0.57, 95% CI 0.35-0.96, p = 0.029). High responders had significant mean changes in IgG antibody titers from T0 to each time point from T1 to T5 (5 years post-vaccination) for both measles and rubella. The annual decline in IgG titers was predicted to be 2.14 (p = 0.002) for measles and 3.15 (p = 0.51) for rubella in high responders. Despite high antibody titers, these levels decline over time, emphasizing the importance of regular monitoring and potential revaccination.

Indexed as

Hematopoietic Stem Cell TransplantationMeaslesMeasles VaccineRubellaRubella VaccineVaccinationAdultAllograftsAntibodies, ViralFemaleHumansImmunoglobulin GMaleMiddle AgedRetrospective StudiesTransplantation, HomologousAntibodies, ViralImmunoglobulin GMeasles VaccineRubella VaccineAllogenic hematopoietic stem cell transplantationMeaslesRubellaVaccination

Identifiers

PMID40938574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.